Drug-Induced Megaloblastic Anemia  

Oleh:

Hesdorffer, Charles S. ; Longo, Dan L.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 373 no. 17 (Oct. 2015), page 1649-1658.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

More than 50 years ago, Victor Herbert first described the concept that defective nucleoprotein synthesis, attributable to various causes, results in the development of megaloblastic anemia.1 Megaloblastic anemia is characterized by the presence of a hypercellular marrow with large, abnormal hematopoietic progenitor cells with a characteristic finely stippled, lacy nuclear chromatin pattern. These abnormal progenitor cells, or megaloblasts, were first described by Paul Ehrlich in 1880. Leukopenia and thrombocytopenia are frequently present. Although the marrow is hypercellular, many of the cells die within it in a process called ineffective erythropoiesis. Megaloblastosis usually results from a deficiency of vitamin B12 (cobalamin) or folic acid, or a deficiency in their metabolism; however, any interference with the synthesis of purines, pyrimidines, or protein may result in megaloblastosis.2

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali